Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Seneca Valley virus replicons are packaged in trans and have the capacity to overcome the limitations of viral transgene expression.
Journal: Molecular therapy oncolytics
Published: November 01, 2022
Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer.
Journal: Nature communications
Published: March 11, 2022
Soluble Carrier Transporters and Mitochondria in the Immunometabolic Regulation of Macrophages.
Journal: Antioxidants & redox signaling
Published: September 24, 2021
ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity.
Journal: Cancer immunology research
Published: July 16, 2020
Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability.
Journal: Molecular therapy oncolytics
Published: February 13, 2020
CCCTC-Binding Factor Acts as a Heterochromatin Barrier on Herpes Simplex Viral Latent Chromatin and Contributes to Poised Latent Infection.
Journal: mBio
Published: February 14, 2018
Viral gene products actively promote latent infection by epigenetic silencing mechanisms.
Journal: Current opinion in virology
Published: January 09, 2017
A Herpesviral Lytic Protein Regulates the Structure of Latent Viral Chromatin.
Journal: mBio
Published: May 18, 2016
Clues to mechanisms of herpesviral latent infection and potential cures.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: September 23, 2015
Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes.
Journal: Science translational medicine
Published: December 05, 2014
Showing 1-12 of 12
Last Updated: 09/26/2026